Impact Biomedical reported a gross margin of 66.67% and a net margin of -23,333.33% for the quarter ended Jun 2026. These financial ratios cover 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||
| Gross Margin | 85.71% | 94.44% | 66.67% | ||||||||||||||
| EBT Margin | -1,598.00% | -205,028.57% | -8,194.44% | -32,628.57% | -23,333.33% | ||||||||||||
| EBIT Margin | -1,500.00% | -16,471.43% | -5,266.67% | -32,700.00% | -23,400.00% | ||||||||||||
| EBITDA Margin | -1,500.00% | -16,442.86% | -5,261.11% | -32,700.00% | -23,400.00% | ||||||||||||
| Operating Margin | -1,500.00% | -16,471.43% | -5,266.67% | -32,700.00% | -23,400.00% | ||||||||||||
| Net Margin | -1,464.00% | -205,028.57% | -8,194.44% | -32,628.57% | -23,333.33% | ||||||||||||
| FCF Margin | -9,914.29% | -3,405.56% | -6,628.57% | 15,666.67% | |||||||||||||
| Efficiency | |||||||||||||||||
| Inventory AverageInventory Avg. | 0.49M | 0.49M | 0.27M | 0.06M | 0.06M | ||||||||||||
| Assets AverageAssets Avg. | 45.54M | 44.86M | 44.49M | 44.24M | 45.41M | 33.49M | 20.17M | 19.56M | 18.63M | 17.81M | 17.25M | 16.92M | |||||
| Invested CapitalInvested Cap. | 42.66M | 42.45M | 41.37M | 52.41M | 40.05M | 39.83M | 42.36M | 28.19M | 25.09M | 37.32M | 33.95M | ||||||
| Asset Utilization RatioAsset Util. | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||
| Leverage & Solvency | |||||||||||||||||
| Interest Coverage RatioInterest Cover | -5.40 | -9.66 | -10.42 | -7.95 | -8.69 | -10.57 | -9.11 | -3.35 | -2.40 | -3.70 | -97.15 | -3.73 | -4.43 | -3.62 | -34.16 | -10.48 | |
| Debt Ratio | 0.21 | 0.26 | 0.26 | 0.54 | 0.29 | 0.30 | 0.17 | 1.03 | 0.91 | 2.35 | 2.51 | ||||||
| Times Interest Earned | -5.40 | -9.66 | -10.42 | -7.95 | -8.69 | -10.57 | -9.11 | -3.35 | -2.40 | -3.70 | -97.15 | -3.73 | -4.43 | -3.62 | -34.16 | -10.48 | |
| Valuation | |||||||||||||||||
| Price to EarningsP/E | 5.42 | -0.62 | -8.23 | -0.55 | -5.54 | -28.32 | -70.85 | ||||||||||
| Price to SalesP/S | 0.00M | 453.57 | 0.01M | 0.02M | |||||||||||||
| Price to BookP/B | 0.67 | 2.30 | 1.54 | -1.07 | -0.69 | 1.01 | 4.40 | 3.54 | |||||||||
| Enterprise Value | 23.34M | 17.66M | 12.16M | 10.26M | 11.11M | 19.02M | 67.92M | 52.83M | |||||||||
| EV to EBIT | -20.71 | -0.67 | -12.04 | -8.90 | -11.72 | -29.67 | -75.26 | ||||||||||
| EV to EBITDA | -20.75 | -0.67 | -12.05 | -8.91 | -11.73 | -29.67 | -75.26 | ||||||||||
| Market Capitalization | 23.01M | 16.68M | 10.51M | 7.92M | 8.16M | 15.78M | 64.69M | 49.60M | |||||||||
| Price to FCFP/FCF | -22.98 | -16.92 | -15.42 | -11.41 | -13.32 | 159.35 | -139.42 | 105.53 | |||||||||
| EV to FCF | -23.32 | -17.91 | -17.83 | -14.78 | -18.12 | 192.08 | -146.38 | 112.41 | |||||||||
| EV to CFO | -23.32 | -17.91 | -17.83 | -14.78 | -18.12 | 192.08 | -146.38 | 112.41 | |||||||||
| Return Ratios | |||||||||||||||||
| Return on Sales [ROS]ROS | -1,500.00% | -16,471.43% | -5,266.67% | -32,700.00% | -23,400.00% | ||||||||||||
| Return on Capital Employed [ROCE]ROCE | -11.79% | -12.70% | -13.04% | -12.15% | -8.27% | -121.29% | -284.32% | 816.29% | 568.75% | -34.71% | -34.24% | ||||||
| Return on Assets [ROA]ROA | -14.30% | -9.83% | -10.24% | -9.77% | 2.42% | -73.87% | -124.05% | -196.82% | -237.23% | -112.43% | -111.21% |